Shanghai Rongsheng biopharmaceutical Co., Ltd
Quality assured friends sincere employees reassured
The history of Shanghai Rongsheng biopharmaceutical Co., Ltd. can be traced back to the Rongsheng reagent factory established in 1988. As a modern biopharmaceutical enterprise focusing on the R & D, production and sales of vaccines and in vitro diagnostic reagents, it has been adhering to the three heart values of "reassuring quality, sincere friends and reassuring employees" for more than 30 years, and has grown into an evergreen brand in the field of biomedicine in China. The company has successively won the titles of national high-tech enterprise, the Fifth Council member of Shanghai Biomedical Industry Association, and the member of China Vaccine Industry Association. It has been awarded the honorary titles of "specialized and new" small and medium-sized enterprises in Shanghai, and "little giant of science and technology in Shanghai". The company has participated in the research of the national major science and technology project "clinical trial and key technology research of new tuberculosis vaccine", The scientific research project "innovative design, large-scale and efficient preparation and application of genetic engineering antigens for infectious disease diagnosis" participated by the company has won the second prize of Beijing Science and technology award.
Decades of experience in immune technology and products
Rongsheng biology regards innovation as life and strictly controls quality
At present, the company has nearly 50 patents, including those authorized and under application. In addition to chickenpox vaccine products, the company also has nearly 60 products of immune and biochemical diagnostic reagents.
In the field of vaccines, in 2017, Rongsheng company successfully listed the "live attenuated varicella vaccine" with an exclusive invention patent. Based on the company's advanced cell factory platform, the production process did not add gelatin, human albumin and other exclusive processes, as well as the more stringent product registration standards compared with the Pharmacopoeia, "live attenuated varicella vaccine" was favored with a very low incidence of adverse reactions.
In the field of diagnostic reagents, Rongsheng company is the honorary chairman unit of the in vitro diagnosis branch of the National Health Industry Association. Rongsheng enzyme-linked immunosorbent diagnostic reagent has always been famous in the domestic diagnostic medicine community for its high sensitivity and specificity. Rongsheng syphilis toluidine red unheated serum test diagnostic reagent has the advantages of simple operation, independent of testing equipment, short test time, etc. for its agglutination test, the number of batches issued in China is firmly in the forefront.
Be a person in charge of the biomedical industry for human health
Rongsheng's products embody the Shanghai spirit of "embracing all rivers, pursuing excellence" and the Shanghai style quality of "planting in Shanghai and abiding by ingenuity".
With the mission of "being a good product for relatives to use at ease", Rongsheng adheres to the combination of independent innovation and top-notch cooperation, and has formed a multi-level R & D pipeline and rich project reserves. At present, there are 8 vaccine projects under research, including the development and clinical research of varicella attenuated live vaccine by cell factory process, the new production line and process development and comparability research of varicella attenuated live vaccine with an annual output of 10million copies, varicella attenuated live vaccine for people aged 13 and above, freeze-dried human rabies vaccine (Vero cells), freeze-dried human rabies vaccine (human diploid cells), varicella zoster vaccine Tetravalent influenza virus split vaccine (MDCK cells) and 16 valent pneumococcal polysaccharide conjugate vaccine. Among them, the cell factory process live attenuated varicella vaccine has been approved for drug (supplementary) registration in 2021 and is on the market. It is continuing to carry out clinical immune persistence research; The production line of live attenuated varicella vaccine with an annual output of 10million copies has entered the process validation stage; The live attenuated varicella vaccine and freeze-dried rabies vaccine for human use (Vero cells) for people aged 13 and above have obtained the approval documents for phase III clinical trials.
The company also reserves 13 in vitro diagnostic reagent projects, of which 7 applications for registration of single and multiple joint diagnostic kit products for infectious diseases such as AIDS, hepatitis C, hepatitis B and syphilis have been accepted by the regulatory authorities. At present, the company is in the stage of technical review, thus forming a rich matrix of characteristic products in the field of in vitro diagnostic reagents for infectious diseases.
Rongsheng, the glory in office, the grand event can be expected!
Follow official wechat
